Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.89 CAD | -0.17% | -0.17% | +2.26% |
Mar. 11 | National Bank Revises 2024, 2025 Estimates for Dexterra Group Following Q4 Results | MT |
Mar. 11 | Dexterra Upgraded to Outperform at Raymond James | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With a P/E ratio at 11.22 for the current year and 9.45 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.41 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Hotels, Motels & Cruise Lines
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.26% | 276M | B- | ||
+6.64% | 69.42B | C+ | ||
+11.02% | 50.54B | B | ||
+11.59% | 16.25B | A- | ||
+16.72% | 15.31B | C+ | ||
+20.75% | 11.17B | A- | ||
+34.52% | 9.7B | A- | ||
+13.56% | 5.05B | A | ||
+8.26% | 4.64B | C- | ||
+24.16% | 3.79B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXT Stock
- Ratings Dexterra Group Inc.